A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion Criteria
2.1 Scope of Work
2.2 Key Questions Answered in the Report
Research Methodology
4.1 Market Overview
4.2 Market Footprint and Potential Growth Scenario
4.2.1 Realistic Growth Scenario
4.2.2 Optimistic Growth Scenario
4.2.3 Pessimistic Growth Scenario
4.3 Evolution of Gene Editing Technologies
4.4 Clinical Trials
5.1 Regulatory Landscape
5.1.1 Legal Requirements and Frameworks in the U.S.
5.1.1.1 Clinical Trial Authorization
5.1.1.2 Marketing Authorization
5.1.1.3 USFDA Guidelines for BLA Submission
5.1.1.4 Post-Authorization Regulations
5.1.2 Legal Requirements and Frameworks in Europe
5.1.2.1 EMA Biologics License Application Process
5.1.2.2 Centralized Procedure
5.1.2.3 Decentralized Procedure
5.1.2.4 Mutual-Recognition Procedure
5.1.2.5 National Procedure
5.1.3 Legal Requirements and Frameworks in Asia-Pacific
5.1.3.1 Legal Requirements and Framework in Japan
5.1.4 Expedited Regulatory Designations Around the World
5.2 Product Benchmarking
5.2.1 Product Benchmarking (by Technology)
5.2.2 Comparative Analysis
5.3 Technology Adoption Matrix
5.4 Industry Trends
5.4.1 Leveraging Collaboration as a Major Key Strategies to Create Opportunities for Gene Editing Technologies
5.4.2 Growing Focus on Gene Therapies
5.5 Patent Analysis
5.5.1 Patent Analysis (by Year)
5.5.2 Patent Analysis (by Technology)
5.5.3 Patent Analysis (by Region)
5.5.4 Patent Analysis (by Country)
6.1 Business Drivers
6.1.1 Introduction of New Technologies Fuelling the Growth of Gene Editing Technologies
6.1.2 Increasing Investments and Funding Opportunities in Gene Editing Space
6.1.3 Increased Demand for Personalized Medicines
6.1.4 Impact Analysis
6.2 Business Restraints
6.2.1 Limited Expertise and Facilities for Gene Editing Technologies
6.2.2 Ethical Considerations and Their Consequences Regarding Human Gene Editing
6.2.3 Impact Analysis
6.3 Business Opportunities
6.3.1 Increasing Numbers of Clinical Trials Utilizing Gene Editing Technologies for the Treatment of Genetic Diseases
6.3.2 Growing Applications of Gene Editing Technologies in Agri-Food Tech
7.1 Key Developments and Strategies
7.1.1 Funding Activities
7.1.2 New Offerings
7.1.3 Mergers and Acquisitions
7.1.4 Partnerships, Alliances, and Business Expansions
7.1.5 Regulatory and Legal Activities
7.2 Key Development Analysis
7.3 Company Share Analysis
8.1 Overview
8.2 Gene Editing Products
8.2.1 Kits and Enzymes
8.2.1.1 CRISPR
8.2.1.1.1 Vector-Based Cas9
8.2.1.1.2 DNA-Free Cas9
8.2.1.2 Non-CRISPR
8.2.2 Antibodies
8.2.3 Libraries
8.2.4 Accessories
8.3 Gene Editing Services
9.1 Overview
9.2 CRISPR Gene Editing Technology
9.3 Non-CRISPR Gene Editing Technology
9.3.1 Zinc-Finger Nucleases (ZFNs)
9.3.2 TAL Effector Nucleases (TALENs)
9.3.3 Meganucleases
10.1 Overview
10.2 Agricultural
10.3 Biomedical
10.3.1 Drug Discovery
10.3.2 Gene Therapy
10.3.3 Diagnostics
11.1 Overview
11.2 Academic Institutes and Research Centers
11.3 Life Sciences Companies
11.4 Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs)
12.1 Overview
12.2 North America
12.2.1 North America Gene Editing Technologies Market (by Application)
12.2.2 North America Gene Editing Technologies Market (by Technology)
12.2.3 North America Gene Editing Technologies Market (by Country)
12.2.3.1 U.S.
12.2.3.1.1 U.S. Gene Editing Technologies Market (by Application)
12.2.3.1.2 U.S. Gene Editing Technologies Market (by Technology)
12.2.3.2 Canada
12.2.3.2.1 Canada Gene Editing Technologies Market (by Application)
12.2.3.2.2 Canada Gene Editing Technologies Market (by Technology)
12.3 Europe
12.3.1 Europe Gene Editing Technologies Market (by Application)
12.3.2 Europe Gene Editing Technologies Market (by Technology)
12.3.3 Europe Gene Editing Technologies Market (by Country)
12.3.3.1 Germany
12.3.3.1.1 Germany Gene Editing Technologies Market (by Application)
12.3.3.1.2 Germany Gene Editing Technologies Market (by Technology)
12.3.3.2 U.K.
12.3.3.2.1 U.K. Gene Editing Technologies Market (by Application)
12.3.3.2.2 U.K. Gene Editing Technologies Market (by Technology)
12.3.3.3 Switzerland
12.3.3.3.1 Switzerland Gene Editing Technologies Market (by Application)
12.3.3.3.2 Switzerland Gene Editing Technologies Market (by Technology)
12.3.3.4 France
12.3.3.4.1 France Gene Editing Technologies Market (by Application)
12.3.3.4.2 France Gene Editing Technologies Market (by Technology)
12.3.3.5 Spain
12.3.3.5.1 Spain Gene Editing Technologies Market (by Application)
12.3.3.5.2 Spain Gene Editing Technologies Market (by Technology)
12.3.3.6 Italy
12.3.3.6.1 Italy Gene Editing Technologies Market (by Application)
12.3.3.6.2 Italy Gene Editing Technologies Market (by Technology)
12.3.3.7 Rest-of-Europe
12.3.3.7.1 Rest-of-Europe Gene Editing Technologies Market (by Application)
12.3.3.7.2 Rest-of-Europe Gene Editing Technologies Market (by Technology)
12.4 Asia-Pacific
12.4.1 Asia-Pacific Gene Editing Technologies Market (by Application)
12.4.2 Asia-Pacific Gene Editing Technologies Market (by Technology)
12.4.3 Asia-Pacific Gene Editing Technologies Market (by Country)
12.4.3.1 China
12.4.3.1.1 China Gene Editing Technologies Market (by Application)
12.4.3.1.2 China Gene Editing Technologies Market (by Technology)
12.4.3.2 Japan
12.4.3.2.1 Japan Gene Editing Technologies Market (by Application)
12.4.3.2.2 Japan Gene Editing Technologies Market (by Technology)
12.4.3.3 India
12.4.3.3.1 India Gene Editing Technologies Market (by Application)
12.4.3.3.2 India Gene Editing Technologies Market (by Technology)
12.4.3.4 Australia
12.4.3.4.1 Australia Gene Editing Technologies Market (by Application)
12.4.3.4.2 Australia Gene Editing Technologies Market (by Technology)
12.4.3.5 Singapore
12.4.3.5.1 Singapore Gene Editing Technologies Market (by Application)
12.4.3.5.2 Singapore Gene Editing Technologies Market (by Technology)
12.4.3.6 South Korea
12.4.3.6.1 South Korea Gene Editing Technologies Market (by Application)
12.4.3.6.2 South Korea Gene Editing Technologies Market (by Technology)
12.4.3.7 Rest-of-Asia-Pacific
12.4.3.7.1 Rest-of-Asia-Pacific Gene Editing Technologies Market (by Application)
12.4.3.7.2 Rest-of-Asia-Pacific Gene Editing Technologies Market (by Technology)
12.5 Latin America
12.5.1 Latin America Gene Editing Technologies Market (by Application)
12.5.2 Latin America Gene Editing Technologies Market (by Technology)
12.5.3 Latin America Gene Editing Technologies Market (by Country)
12.5.3.1 Brazil
12.5.3.1.1 Brazil Gene Editing Technologies Market (by Application)
12.5.3.1.2 Brazil Gene Editing Technologies Market (by Technology)
12.5.3.2 Mexico
12.5.3.2.1 Mexico Gene Editing Technologies Market (by Application)
12.5.3.2.2 Mexico Gene Editing Technologies Market (by Technology)
12.5.3.3 Rest-of-Latin America
12.5.3.3.1 Rest-of-Latin America Gene Editing Technologies Market (by Application)
12.5.3.3.2 Rest-of-Latin America Gene Editing Technologies Market (by Technology)
12.6 Rest-of-the-World
12.6.1 Rest-of-the-World Gene Editing Technologies Market (by Application)
12.6.2 Rest-of-the-World Gene Editing Technologies Market (by Technology)
13.1 Addgene
13.1.1 Company Overview
13.1.2 Role of Addgene in the Global Gene Editing Technologies Market
13.1.3 Major Products: Key Specifications
13.1.4 Key Competitors
13.1.5 Analyst Perspective
13.2 BRAIN Biotech AG
13.2.1 Company Overview
13.2.2 Role of BRAIN Biotech AG in the Global Gene Editing Technologies Market
13.2.3 Major Product: Key Specifications
13.2.4 Key Competitors
13.2.5 Financials
13.2.6 Key Insights about the Financial Health of the Company
13.2.7 Analyst Perspective
13.3 Cellectis S.A.
13.3.1 Company Overview
13.3.2 Role of Cellectis S.A. in the Global Gene Editing Technologies Market
13.3.3 Major Product: Key Specifications
13.3.4 Key Competitors
13.3.5 Financials
13.3.6 Key Insights about the Financial Health of the Company
13.3.7 Analyst Perspective
13.4 Creative Biolabs
13.4.1 Company Overview
13.4.2 Role of Creative Biolabs in the Global Gene Editing Technologies Market
13.4.3 Major Products: Key Specifications
13.4.4 Key Competitors
13.4.5 Analyst Perspective
13.5 CRISPR Therapeutics AG
13.5.1 Company Overview
13.5.2 Role of CRISPR Therapeutics AG in the Global Gene Editing Technologies Market
13.5.3 Major Product: Key Specifications
13.5.4 Key Competitors
13.5.5 Financials
13.5.6 Key Insights about the Financial Health of the Company
13.5.7 Analyst Perspective
13.6 Danaher Corporation
13.6.1 Company Overview
13.6.2 Role of Danaher Corporation in the Global Gene Editing Technologies Market
13.6.3 Major Products: Key Specifications
13.6.4 Key Competitors
13.6.5 Financials
13.6.6 Key Insights about the Financial Health of the Company
13.6.7 Analyst Perspective
13.7 DNA Script
13.7.1 Company Overview
13.7.2 Role of DNA Script in the Global Gene Editing Technologies Market
13.7.3 Major Products: Key Specifications
13.7.4 Key Competitors
13.7.5 Analyst Perspective
13.8 GeneCopoeia, Inc.
13.8.1 Company Overview
13.8.2 Role of GeneCopoeia, Inc. in the Global Gene Editing Technologies Market
13.8.3 Major Product: Key Specifications
13.8.4 Key Competitors
13.8.5 Analyst Perspective
13.9 Magento, Inc.
13.9.1 Company Overview
13.9.2 Role of Magento, Inc. in the Global Gene Editing Technologies Market
13.9.3 Major Products: Key Specifications
13.9.4 Key Competitors
13.9.5 Analyst Perspective
13.10 Merck KGaA
13.10.1 Company Overview
13.10.2 Role of Merck KGaA in the Global Gene Editing Technologies Market
13.10.3 Major Products: Key Specifications
13.10.4 Key Competitors
13.10.5 Financials
13.10.6 Key Insights about the Financial Health of the Company
13.10.7 Analyst Perspective
13.11 New England Biolabs, Inc.
13.11.1 Company Overview
13.11.2 Role of New England Biolabs, Inc. in the Global Gene Editing Technologies Market
13.11.3 Major Products: Key Specifications
13.11.4 Key Competitors
13.11.5 Analyst Perspective
13.12 PerkinElmer Inc.
13.12.1 Company Overview
13.12.2 Role of PerkinElmer Inc. in the Global Gene Editing Technologies Market
13.12.3 Major Product: Key Specifications
13.12.4 Key Competitors
13.12.5 Financials
13.12.6 Key Insights about the Financial Health of the Company
13.12.7 Analyst Perspective
13.13 Precision BioSciences, Inc.
13.13.1 Company Overview
13.13.2 Role of Precision BioSciences, Inc. in the Global Gene Editing Technologies Market
13.13.3 Major Product: Key Specifications
13.13.4 Key Competitors
13.13.5 Financials
13.13.6 Key Insights about the Financial Health of the Company
13.13.7 Analyst Perspective
13.14 Sangamo Therapeutics, Inc.
13.14.1 Company Overview
13.14.2 Role of Sangamo Therapeutics, Inc. in the Global Gene Editing Technologies Market
13.14.3 Major Product: Key Specifications
13.14.4 Key Competitors
13.14.5 Financials
13.14.6 Key Insights about the Financial Health of the Company
13.14.7 Analyst Perspective
13.15 Takara Bio Inc.
13.15.1 Company Overview
13.15.2 Role of Takara Bio Inc. in the Global Gene Editing Technologies Market
13.15.3 Major Products: Key Specifications
13.15.4 Key Competitors
13.15.5 Financials
13.15.6 Key Insights about the Financial Health of the Company
13.15.7 Analyst Perspective
13.16 Thermo Fisher Scientific Inc.
13.16.1 Company Overview
13.16.2 Role of Thermo Fisher Scientific Inc. in the Global Gene Editing Technologies Market
13.16.3 Major Products: Key Specifications
13.16.4 Key Competitors
13.16.5 Financials
13.16.6 Key Insights about the Financial Health of the Company
13.16.7 Analyst Perspective
Table 1: Global Gene Editing Technologies Market, Impact Analysis
Table 2: Key Questions Answered in the Report
Table 3: Parameters for Realistic, Optimistic, and Pessimistic Growth Scenarios
Table 4: Some of the Ongoing Clinical Trials Utilizing Various Gene Editing Technologies
Table 5: Expedited Regulatory Designations Around the World
Table 6: Global Gene Editing Technologies Market, Product Benchmarking (by Technology)
Table 7: Impact Analysis, Business Drivers
Table 8: Risks and Bioethical Concerns that may Arise from Utilizing CRISPR-Cas9 Technology
Table 9: Impact Analysis, Business Restraints
Table 10: Some of the Gene Editing Applications for Abiotic Stress
Table 11: Some of the Gene Editing Applications for Disease Resistance
Table 12: Global Gene Editing Technologies Market, Key Development Analysis, January 2018- March 2023
Table 13: The Comparison of Various Gene Editing Technologies
Table 14: Some of the Ongoing Clinical Trials Utilizing TALEN Gene Editing Technology
Table 15: Some of the Reported CRISPR-Based Diagnostics
Figure 1: Global Gene Editing Technologies Market, $Billion, 2022-2032
Figure 2: Global Gene Editing Technologies Market: Drivers, Restraints, and Opportunities
Figure 3: Global Gene Editing Technologies Market (by Offering), $Billion, 2022-2032
Figure 4: Global Gene Editing Technologies Market (by Technology), $Billion, 2022-2032
Figure 5: Global Gene Editing Technologies Market (by Application), $Billion, 2022-2032
Figure 6: Global Gene Editing Technologies Market (by Region), $Billion, 2022 and 2032
Figure 7: Global Gene Editing Technologies Market, Share of Key Developments and Strategies (by Category), January 2018- March 2023
Figure 8: Global Gene Editing Technologies Market Segmentation
Figure 9: Global Gene Editing Technologies Market: Research Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Top-Down Approach (Segment-Wise Analysis)
Figure 13: Global Gene Editing Technologies Market: Market Overview
Figure 14: Global Gene Editing Technologies Market, Potential Forecast Scenarios, 2022-2032
Figure 15: Global Gene Editing Technologies Market Size and Growth Potential (Realistic Scenario), $Million, 2022-2032
Figure 16: Global Gene Editing Technologies Market Size and Growth Potential (Optimistic Scenario), $Million, 2022-2032
Figure 17: Global Gene Editing Technologies Market Size and Growth Potential (Pessimistic Scenario), $Million, 2022-2032
Figure 18: Evolution of Gene Editing Technologies, 1994-2020
Figure 19: Clinical Trial Authorization for Gene Editing
Figure 20: Steps for Obtaining Marketing Authorization
Figure 21: EMA Review Timeline
Figure 22: Comparison of Various Gene Editing Technologies
Figure 23: Global Gene Editing Technologies Market, Technology Adoption Matrix
Figure 24: Key Strategies Adopted by Major Players, January 2018- March 2023
Figure 25: Global Gene Editing Technologies Market, Patent Analysis (by Year), January 2018- December 2022
Figure 26: Global Gene Editing Technologies Market, Patent Analysis (by Technology), January 2018- December 2022
Figure 27: Global Gene Editing Technologies Market, Patent Analysis (by Region), January 2018- December 2022
Figure 28: Global Gene Editing Technologies Market, Patent Analysis (by Country), January 2018- December 2022
Figure 29: Global Gene Editing Technologies Market, Total Number of Key Developments, January 2018- March 2023
Figure 30: Funding Activities, January 2018- March 2023
Figure 31: New Offerings, January 2018- March 2023
Figure 32: Mergers and Acquisitions, January 2018- March 2023
Figure 33: Partnerships, Alliances, and Business Expansions, January 2018- March 2023
Figure 34: Regulatory and Legal Activities, January 2018- March 2023
Figure 35: Global Gene Editing Technologies Market, Company Share Analysis, % Share, 2022
Figure 36: Global Gene Editing Technologies Market (by Offering)
Figure 37: Global Gene Editing Technologies Market (Gene Editing Products), $Million, 2022-2032
Figure 38: Global Gene Editing Technologies Market (Kits and Enzymes), $Million, 2022-2032
Figure 39: Global Gene Editing Technologies Market (CRISPR), $Million, 2022-2032
Figure 40: Global Gene Editing Technologies Market (Vector-Based Cas9), $Million, 2022-2032
Figure 41: Global Gene Editing Technologies Market (DNA-Free Cas9), $Million, 2022-2032
Figure 42: Global Gene Editing Technologies Market (Non-CRISPR), $Million, 2022-2032
Figure 43: Global Gene Editing Technologies Market (Antibodies), $Million, 2022-2032
Figure 44: Global Gene Editing Technologies Market (Libraries), $Million, 2022-2032
Figure 45: Global Gene Editing Technologies Market (Accessories), $Million, 2022-2032
Figure 46: Global Gene Editing Technologies Market (Gene Editing Services), $Million, 2022-2032
Figure 47: Global Gene Editing Technologies Market (by Technology)
Figure 48: CRISPR Lexicon
Figure 49: Global Gene Editing Technologies Market (CRISPR Gene Editing Technology), $Million, 2022-2032
Figure 50: Global Gene Editing Technologies Market (Non-CRISPR Gene Editing Technology), $Million, 2022-2032
Figure 51: Global Gene Editing Technologies Market (Zinc-Finger Nucleases (ZFNs)), $Million, 2022-2032
Figure 52: Global Gene Editing Technologies Market (TAL Effector Nucleases (TALENs)), $Million, 2022-2032
Figure 53: Global Gene Editing Technologies Market (Meganucleases), $Million, 2022-2032
Figure 54: Global Gene Editing Technologies Market (by Application)
Figure 55: Advantages of Gene Editing Technologies in Agriculture
Figure 56: Global Gene Editing Technologies Market (Agricultural), $Million, 2022-2032
Figure 57: Global Gene Editing Technologies Market (Biomedical), $Million, 2022-2032
Figure 58: Global Gene Editing Technologies Market (Drug Discovery), $Million, 2022-2032
Figure 59: Gene Editing Technology Mechanism in Gene Therapy
Figure 60: Global Gene Editing Technologies Market (Gene Therapy), $Million, 2022-2032
Figure 61: Global Gene Editing Technologies Market (Diagnostics), $Million, 2022-2032
Figure 62: Global Gene Editing Technologies Market (by End User)
Figure 63: Deployment of Gene Editing Technologies
Figure 64: Global Gene Editing Technologies Market (Academic Institutes and Research Centers), $Million, 2022-2032
Figure 65: Global Gene Editing Technologies Market (Life Sciences Companies), $Million, 2022-2032
Figure 66: Global Gene Editing Technologies Market ((CROs)/(CMOs)) $Million, 2022-2032
Figure 67: Global Gene Editing Technologies Market (by Region)
Figure 68: North America: Market Dynamics
Figure 69: North America Gene Editing Technologies Market, $Billion, 2022-2032
Figure 70: North America Gene Editing Technologies Market (by Application), $Billion, 2022-2032
Figure 71: North America Gene Editing Technologies Market (by Technology), $Billion, 2022-2032
Figure 72: U.S. Gene Editing Technologies Market, $Million, 2022-2032
Figure 73: U.S. Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 74: U.S. Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 75: Canada Gene Editing Technologies Market, $Million, 2022-2032
Figure 76: Canada Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 77: Canada Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 78: Europe: Market Dynamics
Figure 79: Europe Gene Editing Technologies Market, $Billion, 2022-2032
Figure 80: Europe Gene Editing Technologies Market (by Application), $Billion, 2022-2032
Figure 81: Europe Gene Editing Technologies Market (by Technology), $Billion, 2022-2032
Figure 82: Germany Gene Editing Technologies Market, $Million, 2022-2032
Figure 83: Germany Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 84: Germany Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 85: U.K. Gene Editing Technologies Market, $Million, 2022-2032
Figure 86: U.K. Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 87: U.K. Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 88: Switzerland Gene Editing Technologies Market, $Million, 2022-2032
Figure 89: Switzerland Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 90: Switzerland Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 91: France Gene Editing Technologies Market, $Million, 2022-2032
Figure 92: France Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 93: France Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 94: Spain Gene Editing Technologies Market, $Million, 2022-2032
Figure 95: Spain Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 96: Spain Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 97: Italy Gene Editing Technologies Market, $Million, 2022-2032
Figure 98: Italy Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 99: Italy Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 100: Rest-of-Europe Gene Editing Technologies Market, $Million, 2022-2032
Figure 101: Rest-of-Europe Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 102: Rest-of-Europe Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 103: Asia-Pacific: Market Dynamics
Figure 104: Asia-Pacific Gene Editing Technologies Market, $Billion, 2022-2032
Figure 105: Asia-Pacific Gene Editing Technologies Market (by Application), $Billion, 2022-2032
Figure 106: Asia-Pacific Gene Editing Technologies Market (by Technology), $Billion, 2022-2032
Figure 107: China Gene Editing Technologies Market, $Million, 2022-2032
Figure 108: China Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 109: China Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 110: Japan Gene Editing Technologies Market, $Million, 2022-2032
Figure 111: Japan Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 112: Japan Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 113: India Gene Editing Technologies Market, $Million, 2022-2032
Figure 114: India Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 115: India Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 116: Australia Gene Editing Technologies Market, $Million, 2022-2032
Figure 117: Australia Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 118: Australia Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 119: Singapore Gene Editing Technologies Market, $Million, 2022-2032
Figure 120: Singapore Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 121: Singapore Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 122: South Korea Gene Editing Technologies Market, $Million, 2022-2032
Figure 123: South Korea Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 124: South Korea Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 125: Rest-of-Asia-Pacific Gene Editing Technologies Market, $Million, 2022-2032
Figure 126: Rest-of-Asia-Pacific Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 127: Rest-of-Asia-Pacific Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 128: Latin America: Market Dynamics
Figure 129: Latin America Gene Editing Technologies Market, $Billion, 2022-2032
Figure 130: Latin America Gene Editing Technologies Market (by Application), $Billion, 2022-2032
Figure 131: Latin America Gene Editing Technologies Market (by Technology), $Billion, 2022-2032
Figure 132: Brazil Gene Editing Technologies Market, $Million, 2022-2032
Figure 133: Brazil Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 134: Brazil Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 135: Mexico Gene Editing Technologies Market, $Million, 2022-2032
Figure 136: Mexico Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 137: Mexico Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 138: Rest-of-Latin America Gene Editing Technologies Market, $Million, 2022-2032
Figure 139: Rest-of-Latin America Gene Editing Technologies Market (by Application), $Million, 2022-2032
Figure 140: Rest-of-Latin America Gene Editing Technologies Market (by Technology), $Million, 2022-2032
Figure 141: Rest-of-the-World Gene Editing Technologies Market, $Billion, 2022-2032
Figure 142: Rest-of-the-World Gene Editing Technologies Market (by Application), $Billion, 2022-2032
Figure 143: Rest-of-the-World Gene Editing Technologies Market (by Technology), $Billion, 2022-2032
Figure 144: Addgene: Product Portfolio
Figure 145: BRAIN Biotech AG: Product Portfolio
Figure 146: BRAIN Biotech AG: Overall Financials, $Million, 2020-2022
Figure 147: BRAIN Biotech AG: Revenue (by Segment), $Million, 2020-2022
Figure 148: BRAIN Biotech AG: Revenue (by Region), $Million, 2020-2022
Figure 149: BRAIN Biotech AG: R&D Expenditure, $Million, 2020-2022
Figure 150: Cellectis S.A.: Product Portfolio
Figure 151: Cellectis S.A.: Overall Financials, $Million, 2020-2022
Figure 152: Cellectis S.A.: R&D Expenditure, $Million, 2020-2022
Figure 153: Creative Biolabs: Product Portfolio
Figure 154: CRISPR Therapeutics AG: Product Portfolio
Figure 155: CRISPR Therapeutics AG: Overall Financials, $Million, 2020-2022
Figure 156: CRISPR Therapeutics AG: R&D Expenditure, $Million, 2020-2022
Figure 157: Danaher Corporation: Product Portfolio
Figure 158: Danaher Corporation: Overall Financials, $Million, 2020-2022
Figure 159: Danaher Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 160: Danaher Corporation: Revenue (by Region), $Million, 2020-2022
Figure 161: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
Figure 162: DNA Script: Product Portfolio
Figure 163: GeneCopoeia, Inc.: Product Portfolio
Figure 164: Magento, Inc.: Product Portfolio
Figure 165: Merck KGaA: Product Portfolio
Figure 166: Merck KGaA: Overall Financials, $Million, 2020-2022
Figure 167: Merck KGaA: Revenue (by Segment), $Million, 2020-2022
Figure 168: Merck KGaA: Revenue (by Region), $Million, 2020-2022
Figure 169: Merck KGaA: R&D Expenditure, $Million, 2020-2022
Figure 170: New England Biolabs, Inc.: Product Portfolio
Figure 171: PerkinElmer Inc.: Product Portfolio
Figure 172: PerkinElmer, Inc.: Overall Financials, $Million, 2020-2022
Figure 173: PerkinElmer, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 174: PerkinElmer, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 175: PerkinElmer, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 176: Precision BioSciences, Inc.: Product Portfolio
Figure 177: Precision BioSciences, Inc.: Overall Financials, $Million, 2020-2022
Figure 178: Precision BioSciences, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 179: Sangamo Therapeutics, Inc.: Product Portfolio
Figure 180: Sangamo Therapeutics, Inc.: Overall Financials, $Million, 2020-2022
Figure 181: Sangamo Therapeutics, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 182: Takara Bio Inc.: Product Portfolio
Figure 183: Takara Bio Inc.: Overall Financials, $Million, 2020-2022
Figure 184: Takara Bio Inc.: Revenue (by Region), $Million, 2020-2022
Figure 185: Takara Bio Inc.: R&D Expenditure, $Million, 2020-2022
Figure 186: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 187: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 188: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 189: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 190: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
Market Report Coverage
Gene Editing Technologies Market |
|||
Base Year |
2022 |
Market Size in 2022 |
$1.81 Billion |
Forecast Period |
2023-2032 |
Value Projection and Estimation by 2032 |
$16.37 Billion |
CAGR During Forecast Period |
27.50% |
Number of Tables |
15 |
Number of Pages |
240 |
Number of Figures |
190 |
Key Market Players and Competition Synopsis
The success of gene editing technologies has sparked efforts to promote treatments. A stronger focus on the gene editing demand has become essential as the need to cater to the clinical and commercial production of cells, together with the growing amount of substantial clinical data resulting from these technologies, arises. The increased demand for treatments is fuelling the expansion of gene editing technology manufacturers and providing them with numerous opportunities to spread out across different regions and improve their market presence.
Key Companies Profiled
• Addgene
• BRAIN Biotech AG
• Cellectis S.A.
• Creative Biolabs
• CRISPR Therapeutics AG
• Danaher Corporation
• DNA Script
• GeneCopoeia, Inc.
• Magento, Inc.
• Merck KGaA
• New England Biolabs, Inc.
• PerkinElmer Inc.
• Precision BioSciences, Inc.
• Sangamo Therapeutics, Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
How can this report add value to an organization?
Workflow/Innovation Strategy: The gene editing technologies market (by offering) has been segmented into gene editing products and gene editing services. Moreover, the study provides the reader with a detailed understanding of the different applications of gene editing technologies in agricultural and biomedical.
Growth/Marketing Strategy: Gene editing technologies are being used for agricultural, biomedical, and other applications. Various companies are providing gene editing products and services, which is also the key strategy for market players to excel in the current gene editing technologies market.
Competitive Strategy: Key players in the global gene editing technologies market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global gene editing technologies market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Gene Editing Technologies Industry and Technology Overview
The global gene editing technologies market was valued at $1.81 billion in 2022 and is anticipated to reach $16.37 billion by 2032, witnessing a CAGR of 27.50% during the forecast period 2023-2032. The growth in the global gene editing technologies market is expected to be driven by an increase in the need for personalized medicine. In addition, the introduction of new technologies fuelled the growth of gene editing technologies.
Market Lifecycle Stage
The global gene editing technologies market is in progressing phase. The creation, production, and distribution of tools and services for gene editing are under the purview of the gene editing technology market. Utilizing ways to change DNA sequences, gene editing technologies can be used to treat genetic illnesses, create disease-resistant crops, and generate study models for animals. The market for gene editing technology is made up of numerous businesses that sell CRISPR-Cas9, TALENs, and zinc finger nucleases, among other types of gene editing tools. Researchers, pharmaceutical corporations, and biotech companies employ these techniques to create novel treatments, vaccines, and diagnostic devices.
Moreover, manufacturers began to produce application-specific gene editing technologies in recent years.
Impact
Clustered regularly interspaced short palindromic repeats Cas9 (CRISPR-Cas9) and other gene editing technologies have the potential to revolutionize the healthcare sector and have a big impact on the world economy. Treatments for genetic problems and diseases such as cancer, HIV, and cystic fibrosis may become more accurate and successful because of gene editing technology. This might result in lower healthcare expenses and better patient outcomes. New intellectual property rights could be established because of the advancement of gene editing technologies, which would lead to a sharp rise in the number of patent applications.
Market Segmentation:
Segmentation 1: by Offering
• Gene Editing Products
• Gene Editing Services
Based on offering, the gene editing products segment in the global gene editing technologies market dominated in FY2022.
Segmentation 2: by Technology
• CRISPR Gene Editing Technology
• Non-CRISPR Gene Editing Technology
Based on technology, the global gene editing technologies market was dominated by the CRISPR gene editing technology segment in FY2022.
Segmentation 3: by Application
• Agriculture
• Biomedical
Based on application, the biomedical segment accounted for the largest share of the global gene editing technologies market in FY2022.
Segmentation 4: by End User
• Academic Institutes and Research Centres
• Life Sciences Companies
• Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs)
Based on end user, the global gene editing technologies market is dominated by the life sciences companies segment in FY2022.
Segmentation 5: by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World
In 2022 the North America gene editing technologies market dominated the global market with a 42.85% market share, and it is expected to hold its dominance throughout the forecast period 2023-2032. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 29.64% during the forecast period 2023-2032.
Recent Developments in the Global Gene Editing Technologies Market
• In March 2023, Seamless Therapeutics launched with $12.5 million seed financing to advance a transformative gene editing platform based on programmable precision designer recombinases.
• In June 2022, Precision BioSciences, Inc. entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG to develop a custom ARCUS nuclease that would be designed to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta-thalassemia.
• In November 2021, Cytovia Therapeutics, Inc. and Cellectis S.A. expanded their TALEN gene-edited iNK partnership to enable broader collaboration in China.
• In February 2022, Integrated DNA Technologies, Inc. (IDT), a provider of global genomics solutions, introduced Alt-R HDR Donor Blocks to support researchers in advancing scientific breakthroughs in gene editing. This enhanced solution was designed to improve homology-directed repair (HDR) rates in large fragment knock-in experiments.
• In March 2023, Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) Application for NTLA-2002. This was an in vivo investigational therapy based on CRISPR, intended for the treatment of Hereditary Angioedema (HAE).
• In April 2022, Thermo Fisher Scientific Inc.'s latest Gibco CTS TrueCut Cas9 Protein, manufactured under Good Manufacturing Practices (GMP), facilitates genome editing for both research and manufacturing purposes, including research on CAR T-cell therapy.
• In November 2022, Ionis Pharmaceuticals, Inc. and Metagenomi announced a collaboration that may bring together Ionis' extensive knowledge in RNA-targeted therapeutics with Metagenomi's versatile next-generation gene editing systems. The aim of this collaboration was to pursue both established and new genetic targets that may offer the potential for expanding treatment options for patients.
Demand - Drivers and Limitations
The following are the demand drivers for the global gene editing technologies market:
• Introduction of New Technologies Fuelling the Growth of Gene Editing Technologies
• Increasing Investments and Funding Opportunities in Gene Editing Space
• Increased Demand for Personalized Medicines
The market is expected to face some limitations due to the following challenges:
• Limited Expertise and Facilities for Gene Editing Technologies
• Ethical Considerations and Their Consequences Regarding Human Gene Editing
Analyst View
According to Akash Mhaskar, Principal Analyst, BIS Research, “The global gene editing technologies market is flourishing with the advent of time and the introduction of new technologies in the gene editing industry. There is constant ongoing research for the development of novel gene editing technologies. The global gene editing technologies market has witnessed a steady growth in the number of new entrants and investments in gene editing technologies, thereby driving a surge in demand for gene editing products. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the global gene editing technologies market in the near future.”
Gene Editing Technologies Market - A Global and Regional Analysis
Focus on Offering, Technology, Application, End User, and Region - Analysis and Forecast, 2023-2032
Frequently Asked Questions
The term gene editing technologies describes a group of methods used to precisely alter the genetic code of living things. These methods give scientists the ability to specifically modify certain genes or DNA sequences, changing how those genes are expressed or function. Although there are many various kinds of gene editing tools, CRISPR-Cas9 is the one that is most frequently employed. This technique is based on a bacterial defense mechanism that directs the Cas9 protein to specific places in the genome where it can cut DNA using RNA molecules. By delivering a fresh DNA strand that can be inserted into the genome at the cut place, scientists can then employ this process to make precise alterations to the DNA sequence.
New technologies and methods are rapidly emerging to enhance the manufacture and delivery of these medicines, which is driving the market for gene editing technologies. Here are some prevalent patterns in the industry:
· Growing focus on gene therapies: Gene therapy is a rapidly growing field in the healthcare industry, and gene editing technologies are playing a major role in the development of gene therapies. Gene editing tools such as CRISPR-Cas9, zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and meganucleases have made it possible to precisely edit the DNA of cells, opening new possibilities for treating genetic disorders that were previously untreatable.
· Leveraging collaboration is a major key strategy to create opportunities for gene editing technologies: The non-CRISPR-based gene editing market is oligopolistic in nature and consists of very few players. To maintain their market presence and position, and profits while keeping pricing pressure under consideration, the companies must adopt key strategies such as mergers and acquisitions (M&A), new offerings, and business expansions to diversify their business portfolio.
These are only a few illustrations of the major developments in the industry for gene editing technologies. Emerging innovations and technologies are anticipated to emerge as the area develops further, helping to influence the industry's future.
The global gene editing technologies market is currently witnessing several developments, primarily aimed toward bringing new products and services. Major manufacturers of gene editing products, along with the service providers, are actively undertaking significant business strategies to translate success in research and development into the commercial clinical setting. Companies such as Cellectis S.A., Merck KGaA, Thermo Fisher Scientific Inc., and CRISPR Therapeutics AG have majorly adopted partnerships, collaborations, and joint venture strategies.
A new entrant can focus on various gene editing product offerings by established players. The market is fragmented with established market leaders such as Cellectis S.A., Merck KGaA, Thermo Fisher Scientific Inc., and CRISPR Therapeutics AG, who have had their presence in the market for the past many years. The new entrants can focus on their strategy of product launches and global expansions for gene editing technologies.
· The major USP of the report is the inclusion of a wide range of gene editing products, including kits and enzymes, libraries, antibodies, accessories, and gene editing services that utilize CRISPR, ZFNs, TALENs, and meganucleases for various applications such as agricultural, biomedical, and others.
· The report provides numerical projections for the application in each region and country.
· Apart from this, the report focuses on key trends observed in the global gene editing technologies market.
· The report also comprises key regulations, competitive landscape, key drivers and restraints, patent analysis, business model analysis, and company profiles with a detailed analysis of the strategies undertaken by the major company to strengthen its market presence.
· Companies that manufacture and commercialize gene editing products as well as provide gene editing services
· Any new entrant that wants to know where the opportunities lie in the gene editing technologies market
· Any established player that wants to expand its product portfolio or business in a new geography